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Background: This study evaluated the impact of Vernonia amygdalina (VA) on the transcription of key enzymes
involved in cellular modulation of glucose in streptozotocin-induced diabetic rats in a bid to understand the
possible anti-diabetic mechanism of VA.
Methods: The chloroform fraction of VA (200 mg/kg and 400 mg/kg body weight) was administered to SDRs for 7
and 14 days. Thereafter, the expression (transcription) of key carbohydrate regulatory genes was evaluated in
selected tissues - adipose, muscle and liver. Also, the body weight and blood glucose changes were monitored.
Results: A 14-day administration of 200 mg and 400 mg of the extract and metformin (500 mg/kg) showed a
striking decrease (P <0.05) in the expression of the gluconeogenic enzymes - fructose 1,6-bisphosphatase, phosphoenol
pyruvate carboxykinase and glucose 6-phosphatase in the liver and muscle compared to the diabetic control.
These genes were highly expressed in tissues of untreated diabetic rats (P <0.05) indicating severe gluconeogenesis.
Furthermore, the extract as well as metformin significantly increased glucose oxidation via the pentose phosphate
pathway (PPP) i.e. increased expression of the glucose 6-phosphate dehydrogenase (G6PDH) gene (P <0.05) in the liver.
Conversely, the expression of the G6PDH in the muscle and adipose tissues significantly decreased (P <0.05), suggesting
enhanced utilization of NADPH and ribose in the clearance of reactive oxygen species and for expression of other
relevant genes respectively. Also, transcription of the cell proliferation regulatory enzyme, phosphatidylinositol 3-kinase
increased in the liver, but decreased in the muscle and adipose tissues (P <0.05) upon treatment with the extract or
metformin, implying that the liver responded to the VA and metformin treatments more than other organs. The
extract administration also caused a decrease in the expression of key enzymes of glycolysis namely hexokinase
and phosphofructokinase, suggestive of a glucose sparing for ribose and NADPH production in PPP.
Conclusion: Overall, data obtained in this study suggest that VA exerts little or no effect on glycolysis; rather, it may
achieve its anti-diabetic action by a simultaneous suppression of gluconeogenesis and potentiation of glucose oxidation
via PPP pathway, almost exclusively in the liver.
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Diabetes mellitus is described as a disease syndrome
with a collection of metabolic disorders characterized by
chronic hyperglycemia which results from defects in in-
sulin secretion, insulin action, or both [1,2]. The chronic
metabolic disorders include, but are not restricted to
alterations in the metabolism of major energy molecules -
carbohydrates, fats, and proteins [3] that usually culminate
in complications of diabetes. This alteration in the metab-
olism of the energy molecules derives largely from changes
in the activities of defining proteins or enzymes of glucose
smetabolism or transport in target tissues – liver, muscle
and adipose. Consequently these key proteins and/or en-
zymes constitute important checkpoints in the endogen-
ous and exogenous glucose homeostasis; hence can be
exploited in the mechanistic study of both conventional
and potential anti-diabetic drugs.
Several conventional anti-diabetic drugs are known to
exert their therapeutic actions via modulation of these mo-
lecular targets. For instance, the thiazolidinediones (TZDs)
exert their anti-diabetic action by binding to the peroxi-
some proliferator-activated receptor-gamma (PPAR-γ), a
nuclear receptor that regulates the transcription of specific
genes involved in glucose and lipid metabolisms and en-
ergy balance (e.g. lipoprotein lipase, fatty acid transporter
protein, adipocyte fatty acid binding protein, fatty acyl-
CoA synthase, malic enzyme, glucokinase and the GLUT4
glucose transporter genes), in a way that improves insulin
sensitivity in adipose, muscle and the liver tissues [4,5]. On
their part, the biguanides such as metformin function as
anti-diabetic drugs by decreasing hepatic glucose produc-
tion, mainly by inhibiting hepatic gluconeogenesis or re-
duction in hepatic uptake of gluconeogenic substrates and
the stimulation of glucose uptake in muscle [6]. These
effects are achieved by adenosine monophosphate kinase
(AMPK) - mediated transcriptional regulation of genes in-
volved in gluconeogenesis in the liver and those encoding
glucose transporters in the muscle, such as peroxisome
proliferator-activated receptor-γ coactivator 1α and glu-
cose transporter type 4, respectively, consequently enhan-
cing tissue insulin sensitivity and lowering of fasting blood
glucose [7]. By a similar token, mechanistic studies are
usually designed to evaluate the anti-diabetic mechanism
of novel drugs including extracts by assaying the expres-
sion of genes of key enzymes or proteins involved in glu-
cose transport and biotransformation, fat modulation and
cell proliferation.
The traditional claim of the use of Vernonia amygda-
lina Del. (VA) leaves in treatment of diabetes has long
been pharmacologically validated as possessing the po-
tential to lower blood glucose level in experimental dia-
betic models [8-10]. In furtherance we demonstrated in
a recent study that the sequential chloroform extract ra-
ther than the methanol or water extracts of the leaves ofVA is most potent in exerting anti-diabetic activity; and
that the dominant fatty and phytanic acids in this fraction
were most probably responsible for the observed effect
[11]. Although several bioactive compounds have been iso-
lated from VA including Vernodalin, Vernomygdin, Verno-
niosides (A1, A2, A3, A4, B1, B2, B3, D & E), Vernodalol
and Epivernodalol [12], none of these isolated compounds
is shown to be responsible for the anti-diabetic properties
of VA. Moreover, very few studies have considered the
mechanism of anti-diabetic action of VA, beyond the sci-
entific validation of the traditional claim. In some previous
studies, administration of VA extract was shown to cause a
regeneration of the β-cells of the pancreas [9,10,13],
thereby contributing in part to its anti-diabetic effect.
These reports on mechanism are scanty, since the de-
rangements soon after outset go beyond the β-cell seques-
tration, such that regeneration of β-cell alone may not
entirely address the complications. It was therefore neces-
sary to study the impact of VA on the metabolism of
carbohydrate, the biomolecule whose metabolism is s
grossly affected in diabetic condition.
Consequently, the purpose of the present study was to
evaluate changes in mRNA expression of key glucose
modulatory enzymes induced by the active chloroform
extract of VA leaves on the liver, muscle and adipose
tissues, in order to achieve a deeper understanding of
the molecular changes associated with the reported anti-
diabetic activity.
Methods
Preparation of plant extract and fraction
The leaves of Vernonia amygdalina Del. were collected
from a reserve at No. 16, Jalan Bukit Gambir, Penang,
Malaysia. The leaves were identified and a voucher spe-
cimen deposited in the herbarium unit at the School of
Industrial Biotechnology, Universiti Sains Malaysia (vou-
cher number: 11341) for future reference. The extraction
was performed according to the procedure described
previously [11]. Briefly, about 700 g of oven-dried and
powdered leaves were sequentially extracted by macer-
ation in petroleum ether and chloroform at 40°C. The
solvents were replenished daily for 3 days each, and on
the 3rd day, the combined extracts were separately fil-
tered with Whatman No. 1 filter paper and concentrated
in vacuo at 40°C. The concentrated extracts were freeze-
dried to obtain the petroleum ether extract and chloro-
form extracts, respectively. The chloroform extract, the
most potent glucose-lowering extract as indicated from
previous studies was stored in the freezer (−4°C) for use
in the animal experiments.
Animals
Sixty (60) male Sprague Dawley rats (200–250 g) were
obtained from the Animal Research and Service Centre
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were acclimatized to conditions in the animal transit
room (23 ± 5°C, 50 ± 10% relative humidity, and 12 h
dark/light cycle) at the School of Pharmaceutical
Sciences, USM, where the animal experiments were
carried out. Food and water were provided ad libitum
but occasionally withdrawn as appropriate for each
stage of the procedure. The animal procedures were
approved by the Animal Ethics Committee, Universiti
Sains Malaysia [Approval number: USM/Animal Ethics
Approval/2012/ (76) (373)].
Diabetes was induced by intraperitoneal injection of
55 mg/kg b.w. of streptozotocin (Sigma, St Louis, MO,
USA) to overnight fasted rats. After 72 h of STZ injec-
tion, fasting blood glucose (FBG) was measured using
the Accu-check Advantage II Glucose meter (Roche
Diagnostics Co., USA) and rats with FBG (mmol/L) ≥15 ≤
25 were considered diabetic and used in the experiment.
Assessment of anti-hyperglycemic activity
The anti-hyperglycaemic activity of the extract was
assessed in diabetic rats by measurement of changes in
FBG during and at the end of the 14-day study period.
The rats were divided into 5 groups (n =12). Groups 1 and
2 served as normal and diabetic controls, respectively and
both received equivalent volume of 5% Tween 80 (p.o.).
Groups 3–5 received 500 mg/kg of metformin and 200 mg
and 400 mg/kg of the chloroform extract (all reconstituted
in 5% Tween 80), respectively. The treatments were
administered in half doses (i.e., 250, 100 and 200 mg/kg,
respectively) twice per day (morning and evening) during
the 14-day period, to as much as possible provide for a
continuous residual amount of the drug in the animals’
system, hence improved efficacy. The 14-day administra-
tion of extract and distilled water which commenced soon
after the confirmation of diabetic status was done using
oral gavages. Fasting blood glucose (FBG) and body weight
were measured 3 days prior to streptozotocin injection
and on days 0 (72 h after streptozotocin injection), 3, 7, 11
and 14. Six rats each from the 5 groups selected on days 7
and 14 (the end of the study), were sacrificed after euthan-
asia, and the liver, soleus muscle and epididymal adipose
tissues surgically removed for gene expression analysis.
The tissues were immediately rinsed in ice-cold saline
(0.9% NaCl), put in falcon tubes containing TRI reagent
and stored at −80°C until used for RNA extraction.
Total RNA extraction and integrity/purity assessment
Total RNA was extracted from the tissues using TRI Re-
agent, combined phenol and guanidine thiocyanate in a
mono-phase solution obtained from Molecular Research
Center, Inc. 5645 Montgomery Road, Cincinnati, Ohio
45212, USA following the manufacturer’s protocol. Briefly,
50–100 mg of the tissue homogenized in 1 ml of TRIReagent was phase separated into the aqueous, interphase
and organic phases by addition of Bromochloropropane
(BCP). After centrifugation at 12,000 g for 15 min at 4°C,
the uppermost aqueous phase was aspirated and RNA
precipitated from the aqueous solution using isopropanol.
The precipitated RNA was washed with 75% ethanol, solu-
bilized with DEPC water and stored at −80°C for further
use after integrity and purity assessment. The integrity of
the extracted RNA was measured by agarose gel electro-
phoresis: A molten 1% (w/v) solution of agarose in 0.5%
Tris-borate-EDTA (TBE) buffer, stained with 3 μL Eth-
idium bromide was prepared and gently poured onto a
cast positioned with a small comb (to define the sample
application wells) and allowed to set at room temperature
for 20–30 min. The gel was mounted in the electrophor-
esis tank and 0.5% TBE buffer added to cover the gel. The
extracted RNA sample mixed with loading dye (GelRed™)
in a 1: 3–5 ratios was gently applied onto the wells along-
side the control, and the electrophoresis run at 95 V and
400 mA for 35 min. The gels were examined under a UV
transilluminator, and samples that displayed the discrete
28S (approx. 5 kb) and 18S (approx. 2 kb) ribosomal RNA
bands possessed the required integrity. The purity and
yield/concentration of the extracted RNA was quantified
using an Eppendorf nano spectrophotometer (Thermo
Fisher Scientific NanoDrop 8000 spectrophotometer 3411
Silverside Road, Bancroft Building Wilmington, DE 19810
USA) at 260 and 280 nm. Samples with absorbance ratio
A260/280 ≥ 1.8 were considered pure and used for subse-
quent experiments.
First strand cDNA synthesis or reverse transcription of
RNA to cDNA
The Revert Aid First Strand cDNA Synthesis Kit #k1621,
#1622, Lot 00103407 (Thermo Scientific, Wilmington, DE
19810 USA) was used for the cDNA synthesis and the
manufacturer’s prescribed procedure followed. However,
prior to cDNA synthesis, the volumes of the extracted
RNA was adjusted by dilution with nuclease free water to
provide an equimolar concentration of the template RNA
(25 ng/μL) in all samples. Where not used immediately the
reverse transcription product was stored at −80°C until
used. The success of the reverse transcription reaction was
validated with conventional PCR amplification using a
house keeping gene – GAPDH (Glyceraldehyde-3-phos-
phate dehydrogenase).
Amplification of cDNA by conventional PCR
The conventional amplification of the synthesized cDNA
was performed using high capacity Master Mix (0.05 U/μL
Taq DNA polymerase, reaction buffer, 4 mM MgCl2, and
0.4 mM of each dNTP - dATP, dCTP, dGTP and dTTP)
obtained from Thermo Scientific, Wilmington, DE 19810
USA. The total volume (25 μL) for one conventional PCR
Table 1 Outline of thermal cycling conditions
Step Temperature (°C) Time Number of cycles
Initial denaturation 94 10 min 1
Denaturation 94 20 s 40
Annealing 55 20 s
Extension 72 30 s
Final extension 72 10 min 1
Cool down 4 - -
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Mix, 1 μL each of forward and reverse primers, 5 μL of
template cDNA and 5.5 μL of nuclease free water. The
MJ Research PTC-200 Peltier Thermal Cycler (590
Lincoln Street Waltham, Massachusetts 02451, USA)
was used for the amplification with the cycle parame-
ters shown in Table 1.
The primers used in this study were synthesized by
Integrated DNA Technologies, San Diego, USA and
their particulars are shown in Table 2. The PCR prod-
ucts mixed with GelRed™ dye were electrophoresed in
electrophoresis tank using 0.5% TBE buffer and 2%
agarose gel at 80 V run for 90 min. Gels were visual-
ized under UV light and subjected to densitometry
analysis (FlouChem FC2 software) for numerical trans-
position and normalization where GAPDH, the loading
control was used as a reference gene. In each assay, a
no-DNA control was incorporated to check for pos-






PFK-1 (L) Forward 5′-TTACCGATCACCCTC
Reverse 5′-TTCCCCTTAGTGCTG












The data were analyzed by the analysis of variance
(ANOVA) followed by the Dunnet test for post hoc ana-
lysis, using the SPSS professional software, version 17.0.
Differences were considered significant at P <0.05.
Results
Body weight and blood glucose
The body weight and blood glucose changes in response
to a 14-day administration of the active chloroform
extract of Vernonia amygdalina Del. leaves to STZ- in-
duced diabetic rats are shown in Figure 1. The animals
lost 5 – 10 g (2-4%) body weight and a corresponding
16.5 mmol/L (75.5%) rise in blood glucose concentration
upon induction of diabetes. Despite the three treatments
administered, i.e. MET (500 mg of metformin) and VA1
(200 mg of extract) and VA2 (400 mg of extract) the
gradual reduction in body weight was seen to persist
over the treatment period in tandem with the diabetic
control, but at varying rates (Figure 1a). However, the
VA1 treated rats showed a comparative advantage in
weight control over the animals in VA2 or MET groups.
On the other hand a noticeable stepwise reduction in
blood glucose was observed in all treatment groups until
the end of the study (Figure 1b). The glucose-lowering
action was more profound and statistically significant on
days 11 and 14: 41.65% and 48.15% for MET; 29.18%
and 38.08% for VA1 and 14.79% and 19.61% for VA2
respectively. It appears from this observation that
body weight control could be an important index inAmplicon Tm (°C)
GGACTA-3′ 105 bp 61.7
CATCCA-3′
ACCATCA-3′ 69 bp 79
GCTCACTAAAG-3′
GTTCCT-3′ 80 bp 84
GGATCT-3′
GACCATTGG-3′ 67 bp 82
CTCTACA-3′
GCTCACT-3′ 132 bp 62.7
ATGTG-3′
GTGTCCTT-3′ 73 bp 81
TCTATTAT-3′
TCGTT-3′ 99 bp 62.7
GCTACAC-3′
GAAGAC-3′ 72 bp 82
CTGTGA-3′
TGCTACATT-3′ 71 bp 81
GAGTCATTG-3′
Figure 1 Body weight (a) and blood glucose concentration (b) of streptozotocin-induced diabetic rats treated with chloroform fraction
of Vernonia amydalina leaves. Values are expressed as the mean ± SEM; n = 6; * = P <0.05 vs DC.
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tion programme in diabetes therapy.
Glycolytic target genes GK, HK and PFK
mRNA levels of three glycolysis - controlled genes namely
glucokinase (GK), hexokinase (HK) and phosphofructoki-
nase (PFK) were determined in liver, muscle and adipose
tissues of the STZ-induced diabetic rats by conventional
PCR, with glyceraldehydes 3 –phosphate (GADPH) as a
reference gene (Figures 2, 3 and 4). Following intervention
with the chloroform extract and the standard metformin
for 7 and 14 days, significant changes were observed in
the level of the measured genes. Precisely, a 14-dayadministration of 200 mg and 400 mg of VA extracts and
metformin (500 mg) caused a significant increase (P <0.05)
in GK gene expression by 8.0, 4.5 and 9.5 folds in the liver
tissue of STZ-induced diabetic rats respectively (Figure 2a).
On agarose gel electrophoresis stained with ethedium
bromide, the GK gene was not expressed in the muscle
and adipose tissues. Converse to the impact on GK
geneexpression, the HK gene was down-regulated by 1.29
and 1.25 fold (P <0.05) in the liver tissues of MET and
VA1 treated animals respectively (Figure 3a). A
down-regulation in the expression of the HK gene
was also observed in muscle tissue - 2.15, 2.15 and 2.80
folds (P <0.05) in the MET, VA1 and VA2 groups
Figure 2 Glucokinase (GK) and glucose 6-phosphatase (G6Pase) expressions in the liver tissues of streptozotocin-induced diabetic rats
treated with chloroform fraction of Vernonia amydalina leaves. Values are expressed as the mean ± SEM; n = 3; * = P <0.05 vs DC.
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extract could effectively down-regulate the HK gene ex-
pression by 1.49 and 1.84 folds for VA1 and VA2 groups
(P <0.05) respectively (Figure 3c). Metformin administra-
tion exerted no significant changes in the HK gene of the
adipose tissue. The densitometry scanning data indicated
no significant effect of extract treatments on the liver PFK-1
gene (Figure 4a), but a significant down-regulated ex-
pression (P <0.05) in the muscle tissue – 3.17, 2.12 and
3.45 folds in the rats in MET, VA1, and VA2 groups
respectively (Figure 4b).
Gluconeogenic target genes – G6Pase, F16BP and PEPCK
The expression of three gluconeognic target genes
namely glucose 6-phosphatase (G6Pase), fructose 1, 6-
bisphosphatase (F16BP) and phosphoenol pyruvate
carboxykinase (PEPCK) at the mRNA level was de-
termined in the liver and muscle tissues in order to
determine the possible effect of the treatments on glu-
cose modulation via gluconeogenesis. The exclusively
hepatocyte-domiciled G6Pase gene was only mildlyimpacted by the interventions of this study: 3.28 (P <0.05)
and 1.97 folds decreases in VA1 and VA2 respectively after
a 7-day treatment (Figure 2b). The effects of a 14-day
treatment were not statistically different from those ob-
served after 7 days. In the liver, whereas a 7-day treatment
did not cause any significant change in the F16BP gene
expression, after a 14 administration, there was significant
1.32, 1.44 and 1.46 folds down-regulation (P <0.05) in the
MET, VA1 and VA2 groups respectively (Figure 5a). Simi-
lar increases in F16BP gene were also indicated in the
muscle tissue after a 14-day treatment (Figure 5b) thus:
2.70, 2.23 and 2.40 folds increases in MET, VA1 and VA2
animals respectively (P <0.05). Diabetes induction up-
regulated the PEPCK gene expression by 2.88 and 1.83
folds in the liver and muscle tissues respectively, but
suppressed it by 3.08 in the adipose relative to the non-
diabetic rats (P <0.05). After a 7-day intervention with 200
and 400 mg of the VA extracts, the PEPCK gene ex-
pression was significantly reduced by 1.78 and 3.60 folds
(P <0.05) in the liver cells respectively (Figure 6a). The 14-
day intervention changes were not as profound in the
Figure 3 Hexokinase (HK) expression in the liver (a), muscle (b) and adipose (c) tissues of streptozotocin-induced diabetic rats treated
with chloroform fraction of Vernonia amydalina leaves. Values are expressed as the mean ± SEM; n = 3; * = P <0.05 vs DC.
Atangwho et al. BMC Complementary and Alternative Medicine 2014, 14:426 Page 7 of 13
http://www.biomedcentral.com/1472-6882/14/426hepatic cells. In the muscle tissue, the 7-day and 14-day
administration of the extract down- regulated the PEPCK
gene by 3.38 and 2.15 folds in the VA1 respectively and
2.27 and 1.54 folds in the VA2 respectively (P <0.05)
(Figure 6b). Similarly, metformin treatment restrained glu-
coneogenesis by decreasing PEPCK gene expression in atime-dependent manner - 1.21 and 2.65 folds decrease
after 7 and 14 days respectively (P <0.05).
Pentose phosphate pathway target gene – G6PDH
mRNA level of the glucose 6-phosphate dehydrogenase
(G6PDH) gene was determined in the liver, muscles and
Figure 4 Phosphofructokinase (PFK) expression in the liver (a) and muscle (b) tissues of streptozotocin-induced diabetic rats treated
with chloroform fraction of Vernonia amydalina leaves. Values are expressed as the mean ± SEM; n = 3; * = P <0.05 vs DC.
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the impact of VA on glucose oxidation in the pentose
phosphate pathway (PPP), a possible glucose modulation
mechanism in diabetes mellitus. From the results shown
in Figure 7 diabetes induction suppressed liver G6PDH
expression by 1.79 folds; however, a 14-day intervention
with MET, VA1 and VA2, up-regulated its expression by
1.42, 1.32 and 1.98 folds respectively, implying enhanced
glucose utilization in PPP (Figure 7a). A reciprocal of
these observed changes were indicated in the muscle
and adipose tissues; where diabetes induction alone
caused 2.16 and 1.24 folds elevation in the G6PDH gene
expression respectively. The administration of MET,
VA1 and VA2, significantly down-regulated the expres-
sion (P <0.05) by 5.14, 3.99 and 4.28 folds in the muscle
respectively (Figure 7b); and correspondingly 1.47, 2.00
and 2.03 folds decreases were recorded in the adipose
tissue (Figure 7c). By this observation, the extract and
metformin indicate a clear tendency towards inhibition
of PPP in the insulin-dependent tissues, i.e. the muscle
and adipose.Cell proliferation and differentiation of target gene - P13K
The result of P13K gene expression in liver (at the
mRNA level) shown in Figure 8 indicates a decrease in
its expression in the diabetic control relative to the nor-
mal control (P <0.05), an indication that differentiation or
growth of the liver tissues was down-regulated in diabetic
condition. A 14-day intervention with 200 and 400 mg of
VA extract exerted a dose-dependent increase in expres-
sion - 1.28 and 2.68 folds respectively (Figure 8a). In the
muscle, the hitherto increased P13K gene in the diabetic
animals (P <0.05) decreased by 2.70, 3.28 and 3.21 folds
following a 14-day treatment with MET, VA1 and VA2
respectively (P <0.05) (Figure 8b). Similarly, a decrease of
1.43 and 1.80 folds was observed in the adipose for VA1
and VA2 groups P <0.05) (Figure 8c). These observations
suggest a down turn of muscle and adipose tissue differen-
tiation in the intervention groups.
Discussion
The anti-diabetic properties of V. amygdalina, a known
medicinal vegetable have been reported in previous
Figure 5 Fructose 1, 6-bisphosphatase (F16BP) expression in the liver (a) and muscle (b) tissues of streptozotocin-induced diabetic rats
treated with chloroform fraction of Vernonia amydalina leaves. Values are expressed as the mean ± SEM; n = 3; * = P <0.05 vs DC.
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remains yet to be known with certainty the effective
agent responsible for the anti-diabetic action in the plant
and the mechanism of anti-diabetic action of this plant
(vegetable). In our recent study an anti-diabetic assay of
serial extracts prepared from the leaves of the plant indi-
cated with profound observation that the anti-diabetic
activity resides in the non-polar chloroform extract [11].
In furtherance of that study, the present investigation
therefore evaluated the effect of the active chloroform
extract on key enzymes and proteins of carbohydrate
and lipid metabolisms using a molecular approach, with
the aim to understand, at least in part, the anti-diabetic
mechanism of this medicinal vegetable. Streptozotocin-
induced diabetic rat models were used in the 14-day
intervention study.
The chloroform extract administered at two dose
levels initiated and sustained a step-wise and gradual
glucose-lowering action with peak reduction on days 11
and 14. This observation is similar to that in our previ-
ous report, where the chloroform extract exerted thehighest lowering action on glucose after a 14-day adminis-
tration [11]. One striking observation in this study that
contrasts with previous report on the anti-diabetic activity
of VA is the fact that the gradual body weight reduction
persisted over the 14-day period, especially in the group
that received the higher dose of extract (400 mg). It is
likely that fractionation of the whole extract tends to
heighten the toxicity effect of VA. Igile and co-workers
[14] had shown that mice fed saponin fraction from this
plant exhibited features of toxicity including weight reduc-
tion at the end of that study. Later on, Ojiako and co-
workers [15] reported another study in which extracts
from VA leaves were implicated in exerting toxicity action
on the study subjects, mice. The impact of the extract on
body weight tends to suggest that whole extract from VA
leaves might be safer as a medicine compared to its frac-
tions. Tiwari and Rao [16] have in their review indicated
and advocated the use of whole plant extracts in prefer-
ence to isolated and pure compounds from plants articu-
lating several draw backs of pure compounds, prominent
amongst which is increased toxicity.
Figure 6 Phosphoenol pyruvate carboxykinase (PEPCK) expression in the liver (a) and muscle (b) tissues of streptozotocin-induced
diabetic rats treated with chloroform fraction of Vernonia amydalina leaves. Values are expressed as the mean ± SEM; n = 3; * = P <0.05 vs DC.
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HK and PFK-1 genes in the liver, skeletal muscle and
adipose was evaluated in order to understand the effect
of VA on glycolysis as a glucose modulatory target in
diabetes. Whereas the expression of GK, highly de-
creased in hepatocytes of untreated diabetic rat, was
increased at the end of treatment; the HK and PFK-1
genes (decreased or unaltered in diabetic condition, re-
spectively) were decreased significantly at the end of
study in the liver, muscle and adipose tissues. These ob-
servations, particularly the suppression of the glycolysis
pacesetter enzyme gene, PFK-1, clearly indicate that the
extract exerted very little or zero impact on glycolysis in
respect of its mechanism of anti-diabetic action. The in-
creased expression of hepatic GK obviously suggests glu-
cose activation feed-in into a glucose utilization pathway
different from glycolysis, most likely the gluconate path-
way. As a confirmation in this study, the G6PDH gene
expression which was significantly decreased in un-
treated diabetic rats, in conformity with previous report
[17] became highly expressed at the end of the extract
intervention. The G6PDH gene or enzyme is a reportedglucose modulatory target of several anti-diabetic agents
and of some medicinal plants [17,18]. Glucose oxidation
via the G6PDH pathway primarily produces or generates
reducing power –NADPH- needed in synthetic (ana-
bolic) reaction and deactivation of reactive oxygen spe-
cies (ROS) in the cell (antioxidant action).
It is plausible that the NADPH generated from this
activated glucose pathway is used to enhance tissue
storage of glucose in form of triglycerides, a process
that requires NADPH and for the reductive removal of
ROS in a glutathione-dependent pathway. We had shown
in a previous study that VA is able to heighten the activity
of antioxidant enzymes in diabetic rat models [10]. The
gluconate pathway potentiation may also form one of the
mechanisms by which VA exerts antioxidant activity
thereby ameliorating diabetes mellitus. Insulin production
was earlier hypothesized as a valid effect of VA administra-
tion in diabetic condition [13] and insulin is known to
favour tissue storage of the fuel molecules including TGs.
The increased NADPH via G6PDH expression may serve
as a boost to the tissue storage process, with the likely aim
to clear free fatty acids from circulation.
Figure 7 Glucose 6-phosphate dehydrogenase (G6PDH) expression in the liver (a) muscle (b) and adipose (c) tissues of streptozotocin-induced
diabetic rats treated with chloroform fraction of Vernonia amydalina leaves. Values are expressed as the mean ± SEM; n = 3; * = P <0.05 vs DC.
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http://www.biomedcentral.com/1472-6882/14/426As emerging from this study, it was also observed that
the G6PDH expression decreased in the skeletal muscle
and adipose. This could have been a deliberate regulatory
mechanism by the tissue to sustain the clearance of ROS,
engendered by the hepatocyte generated NADPH, since
excess NADPH at any particular time is known toreversibly inhibit the G6PDH enzyme [19]. Moreover,
G6PDH activity has been poorly demonstrated in the
muscle tissues, unlike the red blood cells, where the
G6PDH activity is profound. In a holistic sense, it can be
submitted that the VA-induced suppression in hepatic
glycolysis was necessary to spare glucose for the pentose
Figure 8 Phosphatidylinositol 1, 3-kinase (P13K) expression in the liver (a) muscle (b) and adipose (c) tissues of streptozotocin-induced
diabetic rats treated with chloroform fraction of Vernonia amydalina leaves. Values are expressed as the mean ± SEM; n = 3; * = P <0.05 vs DC.
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http://www.biomedcentral.com/1472-6882/14/426phosphate pathway leading to the formation of NADPH
needed for lipid synthetic reactions and ROS clearing as
well as production of ribose for hepatic cell proliferation.
Phosphatidylinositol 1, 3-kinase, an enzyme involved
in regulation of tissue or cell proliferation via production
of second messengers for signal transduction, was in thisstudy highly expressed in the hepatic cells, but not in
the muscle or adipose. This observation tends to sug-
gests that the hepatocytes, more than the muscle and
adipose tissues are more responsible or impacted by the
VA extract, hence may be more involved in glucose modu-
lation during VA treatment. The potentiated G6PDH
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http://www.biomedcentral.com/1472-6882/14/426pathway may be responsible for this selective tissue prolif-
eration. The G6PDH pathway is known to generate ribose
5-phosphate in the non-oxidative phase, which can be
utilize in the biosynthesis of nucleotides required for the
proliferation of cells. Additionally, the NAPDH produced
by the same pathway is also an indispensable ingredient
needed for deoxyribose nucleotide synthesis [19]. Deoxyri-
bose nucleotides and not ribose nucleotides are needed for
cell proliferation. With respect to the hepatocyte-centered
action, VA tends to behave in a manner similar to metfor-
min, a typical biguanide. VA extract was shown to act in a
manner similar to metformin in our previous studies [11].
It has been noted earlier that biguanides, such as me-
tformin inhibit hepatic gluconeogenesis to achieve anti-
diabetic effect [6]. The inhibition of gluconeogenesis by
VA extract administration was also clearly demonstrated
in the present study as heightened expression of the
G6Pase, F16BP and PEPCK genes, the key regulatory en-
zymes of gluconeogenesis. This observation puts VA leaves
in the same category with known plants and compounds
such as Eugenea jambolana [20], rutin [3] and vernadate
[17] with demonstrated hepatic gluconeogenesis inhibition
as their anti-diabetic mechanism, besides biguanides which
are standard anti-diabetic drugs.
Conclusions
Besides contributing to the scientific validation of the anti-
diabetic properties of Vernonia amygdalina growing in
Malaysia, data emerging from this study on the effect of
the plant extract on the expression of selected genes
clearly suggest that Vernonia amygdalina may exert anti-
diabetic or glucose-lowering action by a simultaneous sup-
pression of gluconeogenesis and potentiation of glucose
oxidation via the pentose phosphate pathway almost exclu-
sively in the liver.
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